[{"data":1,"prerenderedAt":421},["ShallowReactive",2],{"content-route-/en/symptoms-conditions/recurrent-vaginal-yeast-infection":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":19,"projection":165,"alternates":412},"target","/en/symptoms-conditions/recurrent-vaginal-yeast-infection","en-US",{"kind":8,"family":9,"sectionKeys":10},"condition","guidance",[11,12,13,14,15,16,17,18],"definition","stages","diagnosis-states","differentials","options","expected-course","recurrence","evidence",{"kind":8,"title":20,"description":21,"firstPublished":22,"evidenceAsOf":22,"lastUpdated":22,"changeNote":23,"firstLayer":24,"stageRoutes":54,"differentials":58,"relations":72,"body":108},"Recurrent vaginal symptoms: what recurrence changes","Understand why recurrent vaginal symptoms need confirmation and reassessment, what can look similar, and how to prepare a useful treatment history for the next decision.","2026-07-15","Complete initial draft based on the Pathway A orientation and US authority packs.",{"question":25,"answer":26,"keyPoints":27,"confidence":31,"applicability":34,"nextSteps":41},"What changes when vaginal or presumed yeast symptoms keep coming back?","Recurrence changes the next step from repeatedly assuming yeast to confirming the cause and reviewing the pattern, prior tests, species where relevant, treatment use, and response. The episode count can flag possible recurrence, but it cannot establish that every episode was vulvovaginal candidiasis.",[28,29,30],"Current CDC and ISSVD guidance generally uses three or more symptomatic episodes in one year to orient possible recurrence, while older guidance and studies often use four or more.","Microbiologic confirmation is needed before labeling repeated symptoms as recurrent vulvovaginal candidiasis or starting a recurrence-management plan.","Repeated self-treatment can mislead when symptoms overlap with another or coexisting cause, or when symptoms persist, return, worsen, or change.",{"summary":32,"rationale":33},"Strong confidence that recurrence requires confirmation and a reopened assessment; the cause and best option remain individual.","CDC and ISSVD guidance agree on symptom overlap, microbiologic confirmation for recurrent or complicated presentations, and reassessment when symptoms persist or return.",{"appliesTo":35,"excludes":38},[36,37],"Adolescents and adults with repeated vaginal or vulvar symptoms or repeated presumed yeast episodes over 12 months.","People whose symptoms returned after apparent improvement or whose prior treatment did not fully resolve them.",[39,40],"People with an immediate medical emergency or acute emotional crisis, who should use the urgent-help route.","People seeking an individualized treatment regimen; pregnancy, immune status, diabetes, medicines, test results, species, and prior response can change that decision.",[42,46,50],{"label":43,"action":44,"route":45},"Arrange reassessment","If symptoms persisted after over-the-counter treatment, returned within two months, or continued or recurred after prescribed treatment, arrange a clinician visit for evaluation and testing instead of repeating self-treatment.","/en/tools/appointment-planner",{"label":47,"action":48,"route":49},"Build a treatment history","Record episode timing, symptoms, test results, products or prescriptions used, completion, adverse effects, and what improved, persisted, returned, worsened, or changed.","/en/tools/treatment-history",{"label":51,"action":52,"route":53},"Check urgent routes","Review observable urgent triggers; acute emotional crisis support is shown only when that crisis trigger is present, not for recurrence alone.","/en/urgent-help",{"firstTime":55,"recurring":56,"treatmentFailed":57},"/en/start-here/symptoms-now","/en/start-here/recurring","/en/symptoms-conditions/vaginal-yeast-treatment-not-working",[59,63,66,69],{"label":60,"discriminator":61,"route":62},"Bacterial vaginosis, trichomoniasis, or cervicitis","These causes can overlap with discharge, irritation, odor, pain, or other presumed yeast symptoms and need cause-specific assessment.","/en/symptoms-conditions/vaginal-yeast-infection-lookalikes",{"label":64,"discriminator":65,"route":62},"Mixed vaginitis or non-albicans Candida","More than one process may coexist, and species-level identification can matter when symptoms persist despite treatment.",{"label":67,"discriminator":68,"route":62},"Mechanical, chemical, or allergic irritation","Friction or exposure to a product can cause recurrent or persistent symptoms even when no vaginal infection is present.",{"label":70,"discriminator":71,"route":62},"Vulvar, inflammatory, or pain condition","Persistent burning, soreness, skin change, or pain may require assessment for a noninfectious vulvar, inflammatory, or pain condition.",[73,77,80,84,87,90,93,97,100,103,105],{"group":74,"route":75,"label":76},"parent","/en/symptoms-conditions/vaginal-yeast-infection","Vaginal symptoms",{"group":78,"route":62,"label":79},"differential","What can look like a vaginal yeast infection",{"group":81,"route":82,"label":83},"treatment","/en/treatments-evidence/vaginal-yeast-treatment","Vaginal yeast treatment",{"group":81,"route":85,"label":86},"/en/treatments-evidence/topical-vs-oral-vaginal-yeast-treatment","Topical vs oral vaginal yeast treatment",{"group":88,"route":57,"label":89},"recurrenceFailure","When vaginal yeast treatment does not work",{"group":18,"route":91,"label":92},"/en/research/evidence/recurrent-vaginal-yeast-symptoms","Evidence map for recurrent vaginal yeast symptoms",{"group":94,"route":95,"label":96},"research","/en/research/rvvc-diagnostic-experiences-2026","Study summary on RVVC diagnostic experiences",{"group":94,"route":98,"label":99},"/en/research/rvvc-quality-of-life-2019","Study summary on RVVC and quality of life",{"group":101,"route":45,"label":102},"tool","Appointment planner",{"group":101,"route":49,"label":104},"Treatment history",{"group":106,"route":53,"label":107},"safety","Urgent help",{"type":109,"value":110,"toc":161},"minimark",[111,119,125,131,137,143,149,155],[112,113,115],"content-section",{"section-key":11,"title":114},"What recurrence is—and is not",[116,117,118],"p",{},"Current CDC and ISSVD guidance generally uses three or more symptomatic episodes within one year to orient possible recurrent vulvovaginal candidiasis; older guidance and studies often use four or more. This threshold describes a history that deserves a recurrence assessment. It does not prove that yeast caused every episode, that Candida detection alone represents disease, or that recurrence is a personal failure.",[112,120,122],{"section-key":12,"title":121},"First episode, recurrence, or treatment failure",[116,123,124],{},"A first unexplained episode starts with symptom-focused evaluation. Repeated episodes use the recurrence route. No improvement, partial improvement, return after treatment, worsening, or new symptoms also use the treatment-failure route because the original diagnosis and differential need to be reconsidered.",[112,126,128],{"section-key":13,"title":127},"Confirmation changes the options",[116,129,130],{},"Confirmed recurrent candidiasis, recurrent unresolved symptoms, and repeated symptoms attributed to yeast are not equivalent. Microbiologic confirmation is needed before a recurrent-candidiasis plan; culture can identify the species and support susceptibility assessment when symptoms persist. A positive Candida result without compatible symptoms and signs does not by itself establish symptomatic infection.",[112,132,134],{"section-key":14,"title":133},"Why repeating self-treatment can mislead",[116,135,136],{},"Bacterial vaginosis, trichomoniasis, cervicitis, mixed vaginitis, non-albicans Candida, irritation, inflammatory or vulvar disease, and pain conditions can overlap with presumed yeast symptoms. Repeating the same label can delay recognition of an alternative or coexisting cause, while reassessment can change the testing question and the appropriate option.",[112,138,140],{"section-key":15,"title":139},"Prepare the next decision",[116,141,142],{},"Bring the timing and number of episodes; menstrual context and relevant exposures; prior examination, microscopy, culture, or other results; every product or prescription used; whether it was completed as directed; adverse effects; and whether symptoms did not improve, partly improved, returned, worsened, or changed. This history supports evaluation but cannot establish the cause without appropriate examination and testing.",[112,144,146],{"section-key":16,"title":145},"Expected course and reassessment",[116,147,148],{},"An expected-course estimate for confirmed uncomplicated candidiasis does not transfer to every recurrent or unresolved presentation. Persistence or return is a decision point: reassess the diagnosis and testing rather than treating recurrence as proof that the same condition remains.",[112,150,152],{"section-key":17,"title":151},"Burden and targeted support",[116,153,154],{},"Recurrent vulvovaginal candidiasis is associated at group level with lower physical, psychological, sexual, social, and overall quality of life, but those observational findings do not predict any one person's experience. Recurrence alone is not a crisis trigger. If someone says they are thinking about suicide, cannot stay safe, or is in acute emotional crisis, call or text 988 or use 988 Lifeline chat now; call 911 or go to an emergency room for immediate danger or a medical emergency.",[112,156,158],{"section-key":18,"title":157},"Evidence and sources",[116,159,160],{},"The linked evidence map traces the exact recurrence, confirmation, reassessment, expected-course, history, and quality-of-life claims to their populations, limits, original sources, and research summaries. This page remains a draft until its planned pathway relations are available for publication.",{"title":162,"searchDepth":163,"depth":163,"links":164},"",2,[],{"sources":166,"claims":237,"safety":354},[167,175,179,186,193,201,209,216,224,231],{"sourceId":168,"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},"cdc-sti-vvc-2021","Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis","doi:10.15585/mmwr.rr7004a1","https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm","US Centers for Disease Control and Prevention","guideline","2021-07-23",{"sourceId":176,"title":177,"canonicalId":170,"canonicalUrl":178,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},"cdc-sti-vaginal-discharge-2021","Sexually Transmitted Infections Treatment Guidelines, 2021: Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor or Discharge","https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm",{"sourceId":180,"title":181,"canonicalId":182,"canonicalUrl":183,"publisher":172,"sourceType":184,"publicationDate":185,"lastChecked":22},"cdc-candidiasis-testing-2024","Testing and Diagnosis for Candidiasis",null,"https://www.cdc.gov/candidiasis/testing/index.html","regulator","2024-04-24",{"sourceId":187,"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},"issvd-vaginitis-recommendations-2023","International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis","doi:10.59153/adm.rdtv.001","https://www.issvd.org/resources/recommendations-for-the-diagnosis-and-treatment-of-vaginitis","International Society for the Study of Vulvovaginal Disease","2023-03-01",{"sourceId":194,"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":22},"owh-vaginal-yeast-infections-2025","Vaginal yeast infections","Office on Women's Health health topic: vaginal yeast infections","https://womenshealth.gov/a-z-topics/vaginal-yeast-infections","Office on Women's Health, U.S. Department of Health and Human Services","official-care-service","2025-10-24",{"sourceId":202,"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":22},"aballea-rvvc-quality-of-life-2013","Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis in Europe and the USA","doi:10.1186/1477-7525-11-169","https://pubmed.ncbi.nlm.nih.gov/24119427/","Health and Quality of Life Outcomes","observational-study","2013-10-11",{"sourceId":210,"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":207,"publicationDate":215,"lastChecked":22},"fukazawa-rvvc-quality-of-life-2019","Influence of recurrent vulvovaginal candidiasis on quality of life issues","doi:10.1007/s00404-019-05228-3","https://pubmed.ncbi.nlm.nih.gov/31270690/","Archives of Gynecology and Obstetrics","2019-07-03",{"sourceId":217,"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":22},"psychosocial-recurrent-urogenital-review-2023","Psychosocial impact of recurrent urogenital infections: a review","doi:10.1177/17455057231216537","https://pubmed.ncbi.nlm.nih.gov/38099456/","SAGE Publications","other","2023-01-01",{"sourceId":225,"title":226,"canonicalId":227,"canonicalUrl":228,"publisher":229,"sourceType":207,"publicationDate":230,"lastChecked":22},"ford-rvvc-diagnostic-experiences-2026","It's not just thrush, it's recurrent thrush: a qualitative study of patient and clinician perspectives on diagnosing recurrent vulvovaginal candidiasis","doi:10.3399/BJGP.2025.0437","https://pubmed.ncbi.nlm.nih.gov/41628983/","British Journal of General Practice","2026-06-01",{"sourceId":232,"title":233,"canonicalId":234,"canonicalUrl":235,"publisher":233,"sourceType":199,"publicationDate":236,"lastChecked":22},"988-lifeline-us-2022","988 Suicide & Crisis Lifeline","US three-digit crisis service 988","https://988lifeline.org/","2022-07-16",[238,253,264,276,286,298,309,318,329,340],{"claimId":239,"exactClaim":240,"outcome":241,"population":242,"verdict":243,"evidenceLevel":244,"rationale":245,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":248,"sources":249},"vaginal-symptoms-do-not-identify-vvc","Itching, soreness, burning, external dysuria, pain during sex, redness, swelling, and abnormal discharge can occur with vulvovaginal candidiasis, but no one of these symptoms is specific enough to identify candidiasis as the cause.","accurate distinction of vulvovaginal candidiasis from other causes of vulvovaginal symptoms","adolescents and adults with current vulvovaginal symptoms, including people who self-attribute the symptoms to yeast","supported","strong","CDC and ISSVD guideline syntheses agree that candidiasis symptoms overlap with other vaginal and vulvar conditions and cannot establish etiology by themselves.","usual-cautions","active",[],[250,251,252],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":177,"canonicalId":170,"canonicalUrl":178,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"claimId":254,"exactClaim":255,"outcome":256,"population":257,"verdict":243,"evidenceLevel":244,"rationale":258,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":259,"sources":260},"candida-detection-alone-does-not-establish-vvc","Detecting Candida in a vaginal sample without compatible symptoms and signs does not by itself establish symptomatic vulvovaginal candidiasis because asymptomatic colonization occurs.","distinction between asymptomatic Candida colonization and symptomatic vulvovaginal candidiasis","adolescents and adults with Candida detected in a vaginal sample, including those with minimal, nonspecific, or absent symptoms","CDC diagnostic guidance and the ISSVD guideline explicitly distinguish Candida detection or positive culture from symptomatic infection and do not treat asymptomatic detection as proof of disease.",[],[261,262,263],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":181,"canonicalId":182,"canonicalUrl":183,"publisher":172,"sourceType":184,"publicationDate":185,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"claimId":265,"exactClaim":266,"outcome":267,"population":268,"verdict":243,"evidenceLevel":244,"rationale":269,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":270,"sources":271},"rvvc-recurrence-definition","Current CDC and ISSVD guidance generally defines recurrent vulvovaginal candidiasis as three or more symptomatic episodes within one year, but older guidance and studies often use four or more; reaching an episode-count threshold does not replace microbiologic confirmation.","classification of a symptom history as possible recurrent vulvovaginal candidiasis without conflating episode count with confirmed diagnosis","adolescents and adults reporting repeated vulvovaginal symptoms or repeated presumed yeast episodes over 12 months","CDC and ISSVD use a three-or-more symptomatic-episode threshold while the reviewed quality-of-life cohorts use four-or-more definitions. Both guidelines require diagnostic evidence for recurrent or complicated presentations, so the threshold is an orientation category rather than proof that every episode was candidiasis.",[],[272,273,274,275],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":22},{"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":207,"publicationDate":215,"lastChecked":22},{"claimId":277,"exactClaim":278,"outcome":279,"population":280,"verdict":243,"evidenceLevel":244,"rationale":281,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":282,"sources":283},"recurrent-vvc-requires-microbiologic-confirmation","Before labeling repeated vulvovaginal symptoms as recurrent vulvovaginal candidiasis or starting a recurrence-management plan, microbiologic confirmation is needed; culture also identifies the Candida species and supports susceptibility assessment when symptoms persist.","confirmation and species-level classification of recurrent or treatment-persistent vulvovaginal candidiasis","adolescents and adults with repeated suspected yeast episodes, complicated vulvovaginal candidiasis, or symptoms persisting despite antifungal treatment","ISSVD makes positive yeast culture crucial before a recurrent-candidiasis plan and calls culture the confirmation standard; CDC recommends culture or PCR for complicated VVC and consideration of susceptibility testing when symptoms persist.",[],[284,285],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"claimId":287,"exactClaim":288,"outcome":289,"population":290,"verdict":243,"evidenceLevel":291,"rationale":292,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":293,"sources":294},"persistent-returned-vaginal-symptoms-require-reassessment","No improvement, only partial improvement, symptom return after treatment, worsening, or new vulvovaginal symptoms do not confirm residual yeast; they change the situation to unresolved symptoms that require reassessment of the diagnosis and appropriate testing.","recognition of treatment nonresponse or recurrence as diagnostic reassessment states rather than proof of ongoing candidiasis","adolescents and adults with suspected or previously diagnosed vulvovaginal candidiasis whose symptoms do not fully resolve, return, worsen, or change after treatment","moderate","CDC requires clinical evaluation and testing for persistent symptoms after over-the-counter treatment or recurrence within two months and follow-up for persistent or recurrent symptoms. ISSVD emphasizes culture and exclusion of other causes in complicated or persistent presentations. The exact urgency attached to worsening or new observable symptoms remains locale-safety owned.",[],[295,296,297],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":177,"canonicalId":170,"canonicalUrl":178,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"claimId":299,"exactClaim":300,"outcome":301,"population":302,"verdict":243,"evidenceLevel":244,"rationale":303,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":304,"sources":305},"failed-vvc-treatment-broadens-differential","When presumed yeast treatment does not resolve symptoms, the differential should be reopened to include bacterial vaginosis, trichomoniasis, cervicitis, mixed vaginitis, non-albicans Candida, and mechanical, chemical, allergic, inflammatory, vulvar, or pain conditions rather than simply repeating the yeast label.","identification of an alternative or coexisting cause after failed empiric vulvovaginal-candidiasis treatment","adolescents and adults with persistent, recurrent, or changed vulvovaginal symptoms after empiric or diagnosis-directed antifungal treatment","CDC identifies BV, trichomoniasis, cervicitis, and noninfectious mechanical, chemical, and allergic causes in the differential and recommends specialist consideration when symptoms remain unexplained. ISSVD additionally addresses mixed vaginitis, inflammatory vaginitis, vulvodynia, vulvar dermatoses, and non-albicans yeast in persistent presentations.",[],[306,307,308],{"title":177,"canonicalId":170,"canonicalUrl":178,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"claimId":310,"exactClaim":311,"outcome":312,"population":313,"verdict":243,"evidenceLevel":244,"rationale":314,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":315,"sources":316},"uncomplicated-vvc-expected-course","For confirmed uncomplicated vulvovaginal candidiasis treated with a recommended azole regimen, symptom relief and a negative culture occur in about 80% to 90% of patients who complete treatment; routine follow-up is generally unnecessary only when symptoms resolve.","symptom relief and mycologic clearance after completed treatment, with recognition of persistence as outside the usual course","nonpregnant, nonimmunocompromised adolescents and adults with confirmed mild-to-moderate uncomplicated vulvovaginal candidiasis treated with a recommended azole regimen","The current CDC guideline synthesis reports symptom relief and negative cultures in 80% to 90% of treatment completers and separates resolved uncomplicated episodes from persistent or recurrent symptoms that need follow-up. Comparative regimen conclusions remain owned by the Pathway A treatment pack.",[],[317],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"claimId":319,"exactClaim":320,"outcome":321,"population":322,"verdict":243,"evidenceLevel":291,"rationale":323,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":324,"sources":325},"structured-vaginal-history-supports-evaluation","Recording symptom timing and pattern, episode count, menstrual context, relevant exposures, prior test results, treatments used, adherence, adverse effects, and response supports evaluation of recurrent or unresolved vulvovaginal symptoms, but the history cannot establish the cause without appropriate examination and testing.","completeness and interpretability of clinical evaluation for recurrence or treatment failure","adolescents and adults preparing for evaluation of recurrent, persistent, or previously treated vulvovaginal symptoms","CDC specifies the history elements relevant to vaginal symptoms while warning that history alone is diagnostically insufficient. ISSVD ties recurrence decisions to episode pattern, testing, species, and treatment response; a 2026 qualitative study describes documentation, test access, and interpretation as parts of the diagnostic pathway but cannot by itself establish outcome benefit from a tool.",[],[326,327,328],{"title":177,"canonicalId":170,"canonicalUrl":178,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":188,"canonicalId":189,"canonicalUrl":190,"publisher":191,"sourceType":173,"publicationDate":192,"lastChecked":22},{"title":226,"canonicalId":227,"canonicalUrl":228,"publisher":229,"sourceType":207,"publicationDate":230,"lastChecked":22},{"claimId":330,"exactClaim":331,"outcome":332,"population":333,"verdict":243,"evidenceLevel":291,"rationale":334,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":247,"changeHistory":335,"sources":336},"rvvc-associated-with-quality-of-life-burden","Recurrent vulvovaginal candidiasis is associated with lower physical, psychological, sexual, social, and overall health-related quality of life compared with people without recurrence.","health-related quality of life and psychological distress associated with recurrent vulvovaginal candidiasis","adults with culture-confirmed recurrent vulvovaginal candidiasis or survey-defined four-or-more self-reported yeast episodes in 12 months","Two observational studies using validated quality-of-life instruments in Brazil, Europe, and the United States consistently report lower physical and psychological well-being, with a later narrative review finding the same direction. Cross-sectional and self-reported designs limit causal inference and applicability to every individual.",[],[337,338,339],{"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":22},{"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":207,"publicationDate":215,"lastChecked":22},{"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":22},{"claimId":341,"exactClaim":342,"outcome":343,"population":344,"verdict":345,"evidenceLevel":346,"rationale":347,"safetyStatus":246,"evidenceAsOf":22,"lastUpdated":22,"status":348,"changeHistory":349,"sources":350},"rvvc-alone-does-not-justify-targeted-crisis-routing","Recurrence or failed vulvovaginal-candidiasis treatment, without an observable disclosure or sign of acute psychological danger, is sufficient on its own to identify a person who needs condition-specific crisis routing.","validity of recurrence or antifungal-treatment failure alone as a trigger for targeted crisis intervention","adolescents and adults reporting recurrent vulvovaginal candidiasis, recurrent self-attributed yeast symptoms, or failed yeast treatment","not-enough-evidence","unclear","The identified literature supports group-level quality-of-life, anxiety, depression, and distress burdens but does not validate recurrence or treatment failure alone as a predictor or triage criterion for imminent self-harm. General observable crisis disclosures remain important, but their exact trigger, care action, resource, and expiry belong to locale-authority safety records.","blocked",[],[351,352,353],{"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":22},{"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":207,"publicationDate":215,"lastChecked":22},{"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":22},[355,368,389,401],{"safetyId":356,"observableTrigger":357,"careTier":358,"action":359,"applicablePopulations":360,"excludedPopulations":362,"locale":6,"checkedAt":22,"expiresAt":364,"sources":365},"us-vvc-persistent-or-early-return-routine","Vaginal symptoms persist after an over-the-counter yeast treatment, return less than 2 months after treatment, or continue or recur after prescribed treatment.","routine","Arrange a clinician visit for evaluation and testing instead of repeating self-treatment without reassessment.",[361],"adolescents and adults in the United States with vaginal or vulvar symptoms after yeast treatment",[363],"people with a simultaneous medical emergency or acute mental-health crisis, who need the applicable emergency route","2027-01-15",[366,367],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":22},{"safetyId":369,"observableTrigger":370,"careTier":358,"action":371,"applicablePopulations":372,"excludedPopulations":375,"locale":6,"checkedAt":22,"expiresAt":378,"sources":379},"us-vvc-pregnancy-treatment-routine","The person is pregnant, might be pregnant, or becomes pregnant while considering or taking treatment for vaginal yeast symptoms.","Contact the pregnancy-care clinician before self-treating; do not use the exact fluconazole products in DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69 unless the clinician directs their use, and report pregnancy during use promptly.",[373,374],"pregnant or possibly pregnant people in the United States with vaginal yeast symptoms","people who become pregnant while taking the exact referenced fluconazole tablet or suspension products",[376,377],"nonpregnant people not planning pregnancy","users of other products whose labels were not checked by this record","2026-10-15",[380,381,388],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":382,"canonicalId":383,"canonicalUrl":384,"publisher":385,"sourceType":386,"publicationDate":387,"lastChecked":22},"FLUCONAZOLE tablet; FLUCONAZOLE powder, for suspension","DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=737e0fac-a2d2-4053-a0d7-edbfb6248f69","U.S. National Library of Medicine DailyMed; labeler Greenstone LLC","official-product","2026-04-02",{"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":22},{"safetyId":390,"observableTrigger":391,"careTier":358,"action":392,"applicablePopulations":393,"excludedPopulations":395,"locale":6,"checkedAt":22,"expiresAt":364,"sources":398},"us-vvc-compromised-host-routine","The person with vaginal yeast symptoms has poorly controlled diabetes, HIV or another immunocompromising condition, an underlying immunodeficiency, or current corticosteroid or other immunosuppressive therapy.","Arrange clinician evaluation rather than relying on a short course of self-treatment, because diagnosis and response may differ in these populations.",[394],"adolescents and adults in the United States with vaginal yeast symptoms and a listed condition or therapy",[396,397],"people without a listed condition or therapy","people with a simultaneous medical emergency, who need emergency care",[399,400],{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":22},{"safetyId":402,"observableTrigger":403,"careTier":404,"action":405,"applicablePopulations":406,"excludedPopulations":408,"locale":6,"checkedAt":22,"expiresAt":378,"sources":410},"us-rvvc-acute-crisis-emergency","A person dealing with recurrent symptoms or treatment failure says they are thinking about suicide, cannot stay safe, or are in acute emotional crisis.","emergency","Call or text 988, or use 988 Lifeline chat, now for crisis support; call 911 or go to an emergency room for immediate danger or a medical emergency.",[407],"people in the United States with recurrent vaginal symptoms or vaginal-treatment failure who disclose the observable crisis trigger",[409],"people with recurrence or treatment failure but no observable crisis disclosure or acute danger",[411],{"title":233,"canonicalId":234,"canonicalUrl":235,"publisher":233,"sourceType":199,"publicationDate":236,"lastChecked":22},[413,416,419],{"rel":414,"hreflang":6,"href":415},"alternate","https://candipedia.org/en/symptoms-conditions/recurrent-vaginal-yeast-infection/",{"rel":414,"hreflang":417,"href":418},"pl-PL","https://candipedia.org/pl/objawy-i-problemy/nawracajaca-grzybica-pochwy/",{"rel":414,"hreflang":420,"href":415},"x-default",1784685064866]